-
New drug
Good Morning, someone has news about the new drug named Nerandomilast, by Boehringer Ingelhiem?
Best . Massimo
-
16 Replies
-
globenewswire.com
Boehringer’s nerandomilast meets primary endpoint in pivotal phase-III FIBRONEER™-IPF study
Topline data from FIBRONEER™-IPF show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline...
-
Thanks for sharing the link to more information Alex-Marion! I’m curious to see what happens with the development of this drug and from patients who speak with their physicians about it.
Char.
-
-
Apparently, it will be a new drug in the market with better results, in 2025/6
-
My husband used to work in clinical research for this company, which is privately owned by a German family. He worked in cardiac, not pulmonary, drugs. This drug sounds promising. It should be noted it is for IPF patients, not those whose PF has an identifiable cause, such as my autoimmune disease. Mine is Sjogren’s Syndrome, but other autoimmune diseases and other identifiable causes for PF may lead doctors to try different treatments. Of course, doctors can and do prescribe for “off label” indications if they feel a patient would benefit. I just want to point out, this drug is–for now, at least–only for IPF.
-
I have non specific interstitial pneumonia. Do you know if this drug is appropriate for NSIP?
-
Hi Charlene
I think this will work, otherwise wouldn’t apply to fda .
I did ask s Dr, in Toronto general back in May this year, and they dodge the question with a maybe answer.
I also asked for the trial of Bristol Mayer drug, that fir what I read works better and minimum side effect. This trial still going till end 2025.
Because in 1 year all the patented drugs loose their monopoly, I imagine, they will supply the market with a better one.
Bi 1015550 realy work well in the 12 weeks phase 2, improved fvc, compared yo placebo.
-
Somthing more that looks possitive.
https://6abc.com/temple-lung-center-idiopathic-pulmonary-fibrosis-scar-tissue-breathe/13577878/
6abc.com
Fibroneer could aid in treating pulmonary fibrosis, stop lung scarring
Pulmonary fibrosis turns the lungs to scar tissue, making it harder and harder to breathe. Help may be on the way as a drug being tested locally aims at giving sufferers their breath back.
-
You really should try Medical Marijuana and CDB together…Cheap $ and I have had IPF for 13 years now and my doc. knows that is why I have made it this long. See my post under treatments or read my profile. God put that plant here and it works…Just saying
-
My doc just applied for compassionate use of this drug on my behalf. I am late stage IPF and emphysema. Only cohorts of the previous Phase 3 trial are eligible for the latest one.
-
I hope you can get approval. They should grant approval to anyone in these circumstances to give hope and chances to live
-
I was in the nerandomilast trial (BI1015550) and after a year my lung function had declined a little, but not much. Then I discovered I was on the placebo. 5 months after starting the real drug, my lung function was more or less back to where it was in 2017, before I had been diagnosed with IPF. So… clearly nerandomilast is not a panacea for everyone but my experience shows that for some, nerandomilast is a total game changer. I really hope it gets FDA approval soon.
-
Thank you for sharing your experience! Very encouraging. Also for being in a trial. I was in a trial but it got stopped for safety reasons 😞
-
-
I am very interested in the nerandomilast and hopeful the FDA will complete the process and give an approval if it is safe and effective. The 2 current anti-fibrotic medications have too many potential severe side effects which has caused me to delay taking medications. I have IPF and understand in clinical trials the side effects of nerandomilast may be more tolerable and the drug may be more effective.
I hope anyone with knowledge of this drug will share timely information. Thank you.
-
The amount of time it’s taking the FDA to approve this drug is very frustrating. My doc is ready to put me on it as soon as it hits the market. I also plan to stay on Ofev too.
-
I read that taking the new drug and discontinuing OFEV had better results than taking both at the same time. Don’t quote me but I think that the mortality rate was reduced by 59% as opposed to 41% in groups taking both. I know that is VERY vague but that was the general gist of the article….
-
-
All,
Late in the afternoon of October 7, 2025 the FDA approved <b style=”font-family: inherit; font-size: inherit;”>nerandomilast for the treatment of IPF. https://www.medpagetoday.com/pulmonology/generalpulmonary/117841
Log in to reply.